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Research findings are particularly important for medication 
choice for first-episode patients as individual prior medica-
tion response to guide treatment decisions is unavailable. 
We describe the first large-scale double-masked randomized 
comparison with first-episode patients of aripiprazole and 
risperidone, 2 commonly used first-episode treatment agents. 
One hundred ninety-eight participants aged 15–40  years 
with schizophrenia, schizophreniform disorder, schizoaffec-
tive disorder or psychotic disorder Not Otherwise Specified, 
and who had been treated in their lifetime with antipsychot-
ics for 2 weeks or less were randomly assigned to double-
masked aripiprazole (5–30 mg/d) or risperidone (1–6 mg/d) 
and followed for 12 weeks. Positive symptom response rates 
did not differ (62.8% vs 56.8%) nor did time to response. 
Aripiprazole-treated participants had better negative symp-
tom outcomes but experienced more akathisia. Body mass 
index change did not differ between treatments but advan-
tages were found for aripiprazole treatment for total and 
low-density lipoprotein cholesterol, fasting glucose, and 
prolactin levels. Post hoc analyses suggested advantages for 
aripiprazole on depressed mood. Overall, if the potential for 
akathisia is a concern, low-dose risperidone as used in this 
trial maybe a preferred choice over aripiprazole. Otherwise, 
aripiprazole would be the preferred choice over risperidone 
in most situations based upon metabolic outcome advan-
tages and some symptom advantages within the context of 
similar positive symptom response between medications.
Key words: clinical trial/treatment response/negative 
symptoms/akathisia/metabolic side effects
Introduction
Optimized treatment of the first episode of schizophrenia 
spectrum disorders offers the potential for better long-
term outcomes. Medication choice is usually guided by 
past response to treatment, the evidence base for treat-
ment options and patient preferences. First-episode 
patients do not have prior antipsychotic response pat-
terns to guide medication choice; thus, the evidence base 
becomes especially important for medication decisions. 
The evidence base ideally should come from first-episode 
studies as response and side effect patterns differ between 
first-episode and multiepisode patients.1
Which antipsychotic to try first? Risperidone is the most 
widely used antipsychotic for first-episode treatment at US 
community facilities followed in frequency by olanzapine, 
aripiprazole, paliperidone, and quetiapine.2 Prior random-
ized first-episode studies comparing olanzapine or quetiap-
ine with risperidone have demonstrated similar efficacy but 
less weight gain with risperidone3,4 and less dyslipidemia.4 
However, even with risperidone, weight gain with first-epi-
sode patients is substantial (eg, 11.6% weight increase after 
3  months of treatment4). The importance of metabolic 
side effects in first-episode treatment choice was recently 
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emphasized by the finding from the national RAISE-ETP 
study that after an average of only 47 days of antipsychotic 
treatment, approximately half of first-episode patients had 
dyslipidemia and half were already overweight or obese.5 
We addressed the important question is whether antipsy-
chotics such as aripiprazole that produce less metabolic 
side effects with chronic patients6 could produce equivalent 
symptom response for first-episode patients as risperidone 
but with less adverse metabolic effects.
Methods
Settings
The study was conducted at 8 New York City area facili-
ties and one facility each in San Antonio, TX and Calgary, 
Alberta, Canada. All sites were not-for-profit institutions 
(either academic centers, community facilities, or public 
hospitals), were located in urban or suburban areas, and 
served diverse communities in terms of economic status 
and racial/ethnic composition. Data were collected from 
December 2005 until April 2013.
Participants
Inclusion Criteria were: (1) current DSM-IV-defined 
diagnosis of schizophrenia, schizophreniform, schizoaf-
fective disorder, or psychotic disorder Not Otherwise 
Specified (NOS); (2) age 15–40; (3) lifetime antipsy-
chotic medication treatment (at any dose) of 2 weeks or 
less; (4) current positive symptoms rated ≥4 (moderate) 
on one or more of the Brief  Psychiatric Rating Scale-
Anchored version (BPRS-A)7 items: conceptual disorga-
nization, grandiosity, hallucinatory behavior, or unusual 
thought content; (5) for women, a negative pregnancy 
test and agreement to use a medically accepted birth con-
trol method; and (6) competent and willing to provide 
informed consent or assent for participants under age 18. 
Exclusion criteria were: (1) meeting DSM-IV criteria for 
current substance-induced psychotic disorder, psychotic 
disorder due to a general medical condition, delusional 
disorder, brief  psychotic disorder, shared psychotic dis-
order, or mood disorder (major depression or bipolar) 
with psychotic features; (2) serious neurological or endo-
crine disorder or medical condition/treatment known to 
affect the brain; (3) medical conditions requiring treat-
ment with a medication with psychotropic effects; (4) 
medical contraindications to risperidone or aripiprazole 
treatment; (5) significant risk of suicidal or homicidal 
behavior; (6) any factor (eg, language limitations) that 
would preclude participants providing informed consent 
or participating in study procedures; (7) diagnosis of 
diabetes (defined as fasting plasma glucose >126 mg/dl) 
or the metabolic syndrome (defined as 3 or more of the 
following: high blood pressure (≥130/85 mm Hg), truncal 
obesity (waist circumference >40 inches for men and >35 
for women), elevated fasting glucose (>110 mg/dl), low, 
high-density lipoprotein (HDL) cholesterol (<40 mg/dl 
for men and <50 mg/dl for women), and elevated triglyc-
erides (≥150 mg/dl)8; and (8) requiring antidepressant or 
mood stabilizer treatment.
Consent Procedures
After complete study description, written informed 
consent was obtained from adult participants and legal 
guardians of participants under 18 years old, who pro-
vided written assent. The study was conducted under the 
auspices of the Feinstein Institute for Medical Research 
Institutional Review Board (IRB) as the coordinating 
center and the IRBs of the clinical sites.
Treatment
Treatment lasted 12 weeks. Participants were stratified 
by site, previous antipsychotic exposure (none vs any), 
and diagnosis (psychotic disorder NOS vs other eligible 
diagnoses) and were randomly assigned on a 1:1 basis 
to double-masked treatment with either aripiprazole 
(5–30 mg/d) or risperidone (1–6 mg/d). Study medication 
was packaged in identically appearing capsules at 3 dif-
ferent dosing levels (level 1: containing 5 mg of aripipra-
zole or 1 mg of risperidone; level 2: 10 mg of aripiprazole 
or 2 mg of risperidone; and level 3: 15 mg of aripiprazole 
or 3 mg of risperidone). The study allowed for prescrip-
tion of 1–2 study capsules per day providing a total of 
6 possible levels of milligrams of daily study medication 
(eg, two level 3 capsules provided either 30 mg of aripip-
razole or 6 mg of risperidone daily). Study medication 
was given at evening but could be moved to other times 
as needed. Inclusion criteria required all participants to 
have very limited prior antipsychotic exposure; any anti-
psychotics being taken at study entry were discontinued. 
The initial daily dose was 1 study capsule (ie, 5 mg of 
aripiprazole or 1 mg of risperidone). Medication doses 
were advanced according to a titration schedule (level 2 
at day 4, level 3 at week 1, two level 2 capsules at week 
4, a level 2 and level 3 capsule at week 6, and two level 3 
capsules at week 8) until response criteria were achieved 
or dose-limiting side effects occurred. Study psychiatrists 
could advance or slow the titration schedule for clinical 
needs. The initial approach for side effect management 
was medication dose reduction. Allowed concomitant 
psychiatric medications were: benztropine for extrapy-
ramidal symptoms (EPS); lorazepam or propranolol 
for akathisia; lorazepam (followed by sodium amytal or 
chloral hydrate as alternatives) for agitation or anxiety; 
lorazepam, zolpidem, or ramelteon for insomnia. Given 
the metabolic effects of antipsychotics, participants also 
received a Healthy Lifestyles psycho-educational package 
based upon materials developed by the National Institute 
of Diabetes and Digestive and Kidney Diseases’ Weight 
Control Information Network. Topics included: What is 
a healthy diet, Tips for healthy eating, What is a healthy 
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weight, Health risks of being overweight, What makes 
people overweight (with information on potential weight 
gain with antipsychotic treatment), and Getting active. 
For participant safety, any participants who fulfilled met-
abolic syndrome criteria or developed new onset diabetes 
during the trial were removed from controlled treatment.
Assessments
Initial diagnostic eligibility was established with the 
Structured Clinical Interview for DSM-IV Axis I Disorders 
(SCID).9 These data were later reviewed in a consensus 
conference (see Funke et al10) for final diagnostic assign-
ment. Assessments done at baseline, weekly for 4 weeks, 
and then every 2 weeks were: BPRS-A,7 Hillside clinical 
trials version of the Scale for the Assessment of Negative 
Symptoms (SANS),11 Clinical Global Impressions Scale 
(CGI),12 modified Systematic Assessment for Treatment 
Emergent Events (Specific Inquiry) (SAFTEE-SI),13 vital 
signs, Simpson-Angus Scale for EPS,14 and the Barnes 
Akathisia Scale (BAS).15 At baseline and every 4 weeks, 
fasting samples for glucose, lipids, insulin, and prolactin 
were obtained. These metabolic measures were supple-
mented with 2-hour oral glucose tolerance tests (OGTT) at 
baseline and end of study. After an overnight fast, subjects 
were given 100 g of glucose. Glucose and insulin levels were 
obtained at baseline and at 30, 60, 90, and 120 minutes.
To increase assessment uniformity, a central rater team 
performed the diagnostic and psychopathology assess-
ments, traveling to New York area sites in person or 
using secure teleconferencing elsewhere. The same rater 
performed assessments with each participant through-
out that individual’s study participation. Intraclass cor-
relation coefficients for the BPRS items comprising the 
response criteria were for conceptual disorganization 
0.94 (95% CI: 0.76, 0.99); grandiosity 0.92 (95% CI: 
0.80, 0.98); hallucinatory behavior 0.93 (0.76, 0.99); and 
unusual thought content 0.92 (95% CI: 0.82, 0.98) and 
for the SANS global items affective flattening 0.75 (95% 
CI: 0.43, 0.93); alogia 0.66 (95% CI: 0.36, 0.89); avolition-
apathy 0.69 (95% CI: 0.38, 0.91); and asociality-anhedo-
nia 0.52 (95% CI: 0.17, 0.85).
Statistical Analysis
Histograms, q-q plots, and the Shapiro-Wilk test were 
used to assess distribution of continuous variables. Based 
on the distribution, an independent-samples t test or 
Wilcoxon rank-sum test was used to compare the base-
line continuous variables between treatment groups. Chi-
square test was used for categorical variables. Proportions 
between the 2 treatment groups were compared using the 
binomial proportions test. Interrater reliability between 
the raters was assessed using intraclass coefficients.
Since missing values may be dependent on the observed 
outcomes, we assumed the missing data to be missing at 
random, and hence analysis of the longitudinal data was 
conducted utilizing a mixed-models approach. A random 
intercept in the mixed-models was used to account for 
correlation of measurements over time among the partici-
pants; the correlational type was assumed to be unstruc-
tured. The difference in slopes of the outcomes between the 
2 treatment groups was assessed using the group-by-time 
interaction term of the mixed models. The P values and 
F-statistics for the main effects of treatment, time, and for 
the treatment-by-time interaction were based on the type 3 
tests of fixed effects. The denominator degrees of freedom 
for F-statistic in the type 3 tests for fixed effects were com-
puted according to Satterthwaite’s formula, which takes 
into consideration the variance within the group along with 
the sample size and is robust against variance heterogeneity.
Symptom Analyses. The primary analysis compared the 
cumulative 12-week response rates between treatments 
using standard survival analysis methods, ie, Kaplan-
Meier product-limit method and the log-rank test. 
Response criteria required (1) a rating of 3 (“mild”) or less 
on all of the following items of the BPRS-A: conceptual 
disorganization, grandiosity, hallucinatory behavior, and 
unusual thought content and (2) a CGI Improvement rat-
ing of much or very much improved on 2 consecutive rat-
ing assessments (time of response was the date of the first 
of the 2 ratings). Confirmatory positive symptom analyses 
examined the longitudinal patterns of the sum of the rat-
ings for the BPRS-A items used in the response criterion. 
A mixed-models approach was used for these analyses and 
analyses of the longitudinal patterns of negative symptoms 
that examined the SANS global measures affective flatten-
ing, alogia, avolition-apathy, and asociality-anhedonia.
Metabolic Effects. A mixed-models approach was used 
to compare across treatments metabolic effects (body 
mass index [BMI], levels of lipids, glucose, insulin and 
prolactin, and OGTT results).
Motor Effects. Parkinsonism was defined as being 
present if  2 or more of the Simpson-Angus EPS Scale 
items gait, rigidity of major joints, tremor, akinesia, and 
akathisia were rated 2 or 1 item was rated 3 or higher. 
Parkinsonism rates were compared with standard sur-
vival analysis techniques. An overall EPS severity score 
was calculated as the sum of the Simpson-Angus EPS 
Scale items just listed. Longitudinal patterns of EPS 
severity and of akathisia as measured by the global item 
of the BAS were compared using mixed models.
General adverse events from the SAFTEE-SI were 
characterized by descriptive statistics.
Results
Participants
The analysis sample included 198 participants (fig-
ure  1). As shown in table  1, participants were young, 
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mostly male (71%), of diverse ethnic backgrounds, and 
usually from low to lower middle class socioeconomic 
backgrounds. Participants had psychotic symptoms for 
a mean of 125.5 weeks before starting antipsychotics, 
reflecting this two-thirds already met diagnostic criteria 
for schizophrenia despite having no or minimal treat-
ment. At entry, 27.4% of participants assigned to aripip-
razole and 22.4% assigned to risperidone (P = .52) were 
antipsychotic medication naive. Participants had sub-
stantial positive symptoms at study entry (as required by 
study design). Negative symptoms were less pronounced; 
the mean ratings on the SANS global items were approxi-
mately 2 (mild). Participants assigned to aripiprazole and 
risperidone did not differ on any baseline characteristics.
Duration of Treatment and Dose
Aripiprazole and risperidone participants had similar 
lengths of time on controlled treatment (mean length was 8.3 
[SD = 4.9] wk with aripiprazole and 8.2 [SD = 4.9] wk with ris-
peridone [t = 0.15, P = .88]). Three subjects (all on risperidone) 
were removed from controlled treatment before 12 weeks for 
safety concerns: one developed metabolic syndrome, one ful-
filled Research Diagnosis of Tardive Dyskinesia16 criteria, 
and one had hematologic abnormalities. The prescribed 
capsule dosing level did not differ between medications. The 
mean modal level was 2.96 (SD = 1.2) for aripiprazole and 
3.16 (SD = 1.49) for risperidone (P = .20) corresponding to a 
daily milligram dose of 14.8 (SD = 6.0) for aripiprazole and 
3.2 (SD = 1.5) for risperidone. Concomitant medication use 
rates did not differ across conditions. The number of aripip-
razole- vs risperidone-treated participants receiving a con-
comitant medication were: benzodiazepines 66 (66.7%) vs 71 
(74.0%) (P = .34); anticholinergic medications 30 (29.4%) vs 
35 (36.5%) (P = .35); beta blockers 15 (14.7%) vs 9 (9.4%) 
(P = .36); and medications specifically for sleep 2 (2.0%) vs 2 
(2.1%) (P = .99).
Symptom Response
Response Rates. Cumulative response rates did not dif-
fer between aripiprazole (62.8%; 95% CI: 50.8%, 74.8%) 
and risperidone (56.8%; 95% CI: 43.9%, 69.9%) treatment 
(log-rank test, χ2 = 0.26, P = .61). Mean time to response 
with aripiprazole was 8.0 (95% CI: 7.9, 8.1) weeks and 8.2 
(95% CI: 7.3, 9.2) weeks with risperidone.
Symptom Levels. Positive Symptoms There were 
no significant differences between medications and no 
Fig. 1. Study progression.
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medication-by-time interactions in longitudinal analy-
ses of the positive symptom BPRS score (F  =  0.34, 
df  =  8,1134, P  =  .96). Scores improved markedly over 
time (F = 116.65, df = 8,1134, P < .0001).
Negative Symptoms There were no significant dif-
ferences between medications and no medication-by-
time interactions in longitudinal analyses of  the SANS 
global items affective flattening and alogia. Alogia 
scores improved over time (F  =  25.42, df  =  8,1156, 
P < .0001) but affective flattening did not. In contrast, 
analyses revealed a significant medication-by-time inter-
action (F = 2.18, df = 8,1162, P =  .03) with avolition-
apathy and a nonsignificant but trend-level interaction 
(F  =  1.76, df  =  9,1149, P  =  .08) for asociality-anhe-
donia. Asociality-anhedonia significantly improved 
over time (F = 3.29, df = 8,1149, P = .001). Avolition-
apathy improved with aripiprazole and worsened with 
risperidone treatment but the differences were modest 
Table 1. Demographic and Clinical Characteristics of Participantsa
Characteristic All Participants
Aripiprazole-
Treated 
Participants
Risperidone-
Treated 
Participants
N % N % N %
Men 140 71  72  71  68  71
Women 58 29  30  29  28  29
Ethnic background
 African-American 73 37  38  38  35  37
 Asian 39 20  22  22  17  18
 Caucasian 48 24  21  21  27  28
 Hispanic 20 10  11  11  9  9
 Other/mixed 16 9  9  9  7  7
Marital status
 Never married 182 92 92 92 90 94
 Married 4 2 1 1 3 3
 Remarried 1 0.5 1 1 0 0
 Divorced 9 4.5 6 6 3 3
 Unknown 2 1 2 2 - -
Diagnosis
 Schizophrenia 131 66 72 71 59 62
 Schizophreniform disorder 45 23 23 22 22 23
 Schizoaffective disorder 6 3 2 2 4 4
 Psychotic disorder NOS 16 8 5 5 11 11
Mean SD Mean SD Mean SD
Age (y) 22.1 5.6 22.4 5.8 21.8 5.4
Highest educational level (1 = postgraduate; 7 = grade school) 3.9 1.2 4.0 1.4 3.8 1.1
Hollingshead social class
 Participant 4.4 2.5 4.2 0.8 4.6 3.4
 Parent 3.4 2.7 3.3 1.3 3.5 3.6
Age at first psychiatric symptoms (y) 18.1 6.0 18.2 5.9 18.1 6.0
Age at first psychotic symptoms (y) 19.7 5.3 19.8 5.0 19.7 5.6
Duration of psychiatric symptoms before study entry (wk) 203.9 282.1 218.0 317.6 188.8 238.9
Duration of psychotic symptoms before study entry (wk) 125.5 208.8 138.2 243.3 112.0 164.4
Least square means estimates of symptom severity
BPRS-A total score at study entry 45.89 0.86 44.38 0.92
Total of BPRS-A items in response criterion at study entry 14.66 0.38 14.42 0.40
CGI severity score at study entry 4.95 0.11 4.94 0.12
SANS global scores at study entry
 Affective flattening 1.85 0.09 1.74 0.09
 Alogia 2.08 0.08 1.96 0.09
 Avolition-apathy 2.16 0.10 2.02 0.10
 Asociality-anhedonia 2.19 0.08 2.07 0.09
Note: BPRS-A, Brief  Psychiatric Rating Scale-Anchored version; CGI, Clinical Global Impressions Scale; NOS, Not Otherwise 
Specified; SANS, Scale for the Assessment of Negative Symptoms.
aParticipants assigned to aripiprazole and risperidone did not differ on any characteristic.
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(a similar pattern was seen with asociality-anhedonia) 
(figure 2).
Global Symptom Measures There were no significant 
differences between medications and no medication-by-
time interactions in longitudinal analyses of the total 
BPRS (F = 1.17, df = 8,1095, P = .32) and also of CGI 
Severity (F = 0.84, df = 8,1137, P = .57). Scores improved 
markedly over time for both the total BPRS (F = 115.31, 
df = 8,1095, P < .0001) and CGI (F = 105.13, df = 8,1137, 
P < .0001) measures.
Motor Side Effects
Analysis of the BAS global item revealed a significant med-
ication-by-time interaction (F = 2.21, df = 8,1127, P = .03) 
(figure 3). Akathisia scores were significantly more severe 
with aripiprazole compared with risperidone at weeks 1, 
4, and 6. Longitudinal analysis of the presence/absence of 
Parkinsonism revealed no significant medication, time, or 
treatment-by-time effects. Based upon a survival analysis, 
the cumulative rates of Parkinsonism were 14.8% (95% CI: 
7.4%, 22.1%) with aripiprazole and 15.5% (95% CI: 7.1%, 
24.0%) with risperidone (log-rank test, χ2 = 0.11, P = .75). 
Analyses of the extrapyramidal symptom severity score 
found no time or treatment-by-time effects but a significant 
medication effect (F = 5.61, df = 1,197, P = .02); scores were 
significantly worse with aripiprazole compared with risper-
idone at weeks 1, 2, and 4 (supplementary figure 1). Our 
a priori definition of extrapyramidal side effects included 
akathisia. Post hoc, we recalculated an extrapyramidal 
severity score excluding akathisia. Analyses of this sever-
ity score without akathisia again revealed no treatment-by-
time or time effects while the medication effect became only 
trend level (F = 3.13, df = 1,201, P = .08).
Relationship Between Levels of Extrapyramidal 
Symptoms and Avolition-Apathy.
Because extrapyramidal symptoms can be a cause of sec-
ondary negative symptoms, post hoc we examined the 
correlation at each assessment point between severity of 
avolition-apathy and the extrapyramidal severity score. 
Correlations except at week 3 were low (≤0.18) and not 
significant (P > .05). The week 3 correlation was signifi-
cant (P < .001) but still low (0.36).
Metabolic Outcomes
BMI increased over time (F  =  124.09, df  =  8,1102, P < 
.0001) but there were no treatment-by-time or treatment 
effects. Estimated mean baseline vs 12-week BMI was 
23.02 (95% CI: 22.22, 23.82) vs 24.81 (95% CI: 24.01, 
25.62) for aripiprazole-treated participants and 23.22 (95% 
CI: 22.42, 24.02) vs 24.98 (95% CI: 24.17, 25.80) for risper-
idone-treated participants. Analyses of weight revealed the 
same pattern. Estimated kilogram increase in weight from 
baseline to 12 weeks with aripiprazole was 5.04 (95% CI: 
4.16, 5.93) and 6.12 (95% CI: 4.11, 8.14) with risperidone.
Significant treatment-by-time interactions favoring 
aripiprazole were revealed in analyses of total cholesterol 
Fig. 2. SANS Avolition-Apathy Global Score. Medication-by-time interaction, F = 2.18, df = 8,1162, P = .03. SANS, Scale for the 
Assessment of Negative Symptoms.
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and low-density lipoprotein (LDL) cholesterol but not 
in analyses of HDL cholesterol or triglycerides (table 2). 
Analysis of fasting glucose but not fasting insulin levels 
also revealed a significant treatment-by-time interaction, 
again favoring aripiprazole treatment. Analysis of the 
OGTT area under the curve for glucose and for insulin 
revealed no treatment, time, or treatment-by-time effects. 
Analyses of prolactin levels separately by sex revealed 
significant treatment-by-time interactions with both 
women and men. Prolactin levels were significantly less at 
all time points after baseline for aripiprazole compared 
with risperidone.
Other Side Effects
The longitudinal SAFTEE-SI assessment results (sup-
plementary table 1) showed a high rate of  side effects 
with both agents for sleep disturbances and sedation, 
appetite and weight changes, and motor side effects. 
The SAFTEE-SI event with the greatest difference 
between treatments was depression. Post hoc, we exam-
ined longitudinal change in the BPRS item depressive 
mood. This analysis showed a medication-by-treatment 
interaction (F = 2.43, df = 8,1088, P = .02), as with the 
SAFTEE-SI data, favoring aripiprazole (supplemen-
tary figure 2).
Discussion
To our knowledge, our data are the first presented from 
a large double-masked randomized trial comparing 
aripiprazole and risperidone for the acute treatment of 
first-episode schizophrenia and related conditions.
What do the results suggest about choosing between 
aripiprazole and risperidone as the initial antipsychotic? 
Regarding symptom improvement, we found mostly 
equivalent efficacy with a potential advantage for aripip-
razole. Response rates and levels of positive symptom 
improvement were equivalent. Avolition-apathy improved 
with aripiprazole and worsened with risperidone but the 
differences were modest. Extrapyramidal symptoms can 
be a cause of secondary negative symptoms but the lack 
of correlation in our post hoc analyses between levels 
of avolition-apathy and extrapyramidal symptoms sug-
gests that the avolition-apathy findings were not driven 
by this mechanism. Our SAFTEE-SI data and post hoc 
analyses raise the possibility of an advantage for aripip-
razole for depression. The medications did differ on side 
effects. Akathisia was more severe with aripiprazole com-
pared with risperidone. BMI increase did not differ but 
aripiprazole was associated with better outcomes than 
risperidone on total and LDL cholesterol and prolactin. 
Aripiprazole was also associated with better outcomes 
for fasting glucose; this advantage was not seen with fast-
ing insulin or OGTT results.
Comparable first-episode data are very limited. 
Zhang and colleagues17 reported on a randomized, 
but open-label, trial comparing aripiprazole, paliperi-
done, and ziprasidone for first-episode schizophre-
nia. Paliperidone treatment was associated with more 
improvement in Positive and Negative Syndrome Scale 
Fig. 3. Global Barnes Akathisia Scores. Medication-by-time interaction, F = 2.21, df = 8,1127, P = .03.
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(PANSS)18 scores at 13 weeks of  treatment than aripip-
razole or ziprasidone. Aripiprazole was associated with 
more weight gain than either paliperidone or ziprasi-
done. An unusual feature of  this trial was the very low 
dosing of  aripiprazole (5 mg) and ziprasidone (20 mg) 
in comparison with paliperidone (6 mg). How this may 
have affected the results is unknown. Correll and col-
leagues19 followed for 12 weeks 505 youth first starting 
an antipsychotic; antipsychotic choice was by clinician 
decision. The sample included 168 patients taking ris-
peridone and 47 aripiprazole. The analyses compared 
baseline values and 12-week values for each agent stud-
ied (no direct medication comparisons). 95% CIs of 
change differed between aripiprazole and risperidone 
for triglycerides but not for BMI, glucose, insulin, or 
cholesterol.
How do our results compare with data from trials 
with multiepisode patients? Contrary to our symptom 
findings, a recent multiple-treatments meta-analysis6 
of  acute trials found better efficacy for improvement 
in total PANSS or BPRS scores with risperidone com-
pared with aripiprazole. However, in a meta-analysis20 
of  acute trials focused solely on direct comparisons of 
the agents this advantage was not present. Consistent 
with our findings, this meta-analysis found an advantage 
for end point negative symptoms with aripiprazole. Our 
findings differ more with the multiepisode studies on 
side effects, possibly related to an increased vulnerability 
with young patients first starting treatment. We did not 
find differences in BMI change across agents in contrast 
with consistent findings with multiepisode patients.6,20 
Multiepisode studies have found more extrapyramidal 
Table 2. Metabolic Outcomes: Estimated Least Squares Means and SE
Measure Condition Baseline SE Week 4 SE Week 8 SE Week 12 SE
Treatment- 
by-Time 
Interaction
Total cholesterol (mg/dl) F = 4.73, 
df = 3,376, 
P = .003
Aripiprazole 158.25 3.15 157.81* 3.41 162.98* 3.74 163.02** 3.74
Risperidone 157.01 3.30 168.62* 3.62 175.92* 3.77 178.36** 4.10
LDL cholesterol (mg/dl) F = 4.36, 
df = 3,369,  
P < .01
Aripiprazole 86.37 2.60 84.97* 2.78 90.31** 3.02 91.89** 3.02
Risperidone 88.25 2.77 95.49* 3.02 104.10** 3.14 105.62** 3.41
HDL cholesterol (mg/dl) F = 0.83, 
df = 3,372, P = .48
Aripiprazole 55.99 1.37 56.59 1.47 56.25 1.60 55.14 1.60
Risperidone 53.23 1.40 56.60 1.52 55.05 1.57 54.21 1.69
Triglycerides (mg/dl) F = 0.66, 
df = 3,352, P = .59a
Aripiprazole 80.00 4.48 80.78 4.90 87.52 5.44 87.35 5.44
Risperidone 77.41 4.50 86.12 4.96 88.24 5.17 93.17 5.64
Fasting glucose (mg/dl) F = 3.18, 
df = 3,367, P = .03
Aripiprazole 85.06 0.69 86.26 0.76 87.18 0.87 84.22** 0.89
Risperidone 84.60 0.89 85.81 1.03 86.61 1.09 88.24** 1.22
Fasting insulin (uU/ml) F = 0.59, 
df = 3,372, P = .63
Aripiprazole 12.39 1.10 13.06 1.23 13.79 1.40 14.65 1.39
Risperidone 13.10 1.38 12.60 1.54 14.14 1.67 12.18 1.85
Prolactin (ng/ml)
Female participants Aripiprazole 61.84 7.61 11.58*** 8.41 12.11*** 8.97 9.72** 11.60 F = 11.62, 
df = 3,52.8, P < 
.0001
Risperidone 65.52 12.88 129.49*** 14.45 103.50*** 15.25 101.18** 20.81
Male participants Aripiprazole 28.72 3.05 9.05*** 3.21 10.92*** 3.67 6.59*** 4.56 F = 34.13, 
df = 3,205, P < 
.0001
Risperidone 31.50 3.24 54.52*** 3.70 63.06*** 4.00 54.23*** 4.60
Note: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aMain effect of time F = 3.84, df = 3,352, P = .01.
*Difference between treatments, P < .05, **P < .01, ***P < .0001.
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symptoms and akathisia with risperidone.20 Stroup and 
colleagues21 reported outcomes for 72 patients taking ris-
peridone who had preexisting metabolic risk factors and 
who were randomly assigned to remain on risperidone or 
switch to aripiprazole. Participants switched to aripip-
razole at 24 weeks of  follow-up had better triglyceride 
and fasting insulin values but not for total cholesterol or 
LDL cholesterol. Our prolactin findings favoring aripip-
razole over risperidone are consistent with those from 
multiepisode comparison studies6,20 and from studies of 
prolactin levels following switching from risperidone to 
aripiprazole.22
Our study had limitations. Our trial lasted 12 weeks 
which has been a widely used duration in first-epi-
sode acute trials (eg, Lieberman et  al23) but a longer 
trial may have resulted in higher response rates.24 Our 
Healthy Lifestyles education program was designed to 
model services that are available in routine clinical set-
tings. It is possible that our metabolic findings may be 
less severe than would be encountered in clinics treating 
patients without any program. Further, our metabolic 
data capture only the initial effects and not long-term 
effects of  the antipsychotics studied. Our participants 
were required to have moderate or more severe posi-
tive symptoms at entry. Our negative symptom analyses 
therefore only address negative symptoms in the initial 
context of  positive symptoms and may not necessarily 
generalize to negative symptoms in the absence of  posi-
tive symptoms.
Our data have several clinical implications. One is the 
need to follow guideline recommendations (eg, Marder 
et  al25) for laboratory testing for patients treated with 
antipsychotics as our data show that metabolic differ-
ences between antipsychotics can occur in the absence of 
BMI change differences. As in other first-episode stud-
ies (eg, McEvoy et al4), we found high rates of  adverse 
events suggesting the need for close side effect monitor-
ing with first-episode patients. Regarding which anti-
psychotic to choose, we found no difference in positive 
symptom response between agents. Aripiprazole had an 
advantage for negative symptoms but a disadvantage for 
akathisia, possibly reflecting an overall activation effect. 
Even though we did not find a difference in all metabolic 
outcomes, the differences found all favored aripiprazole. 
Overall, if  the potential for akathisia is a concern, low-
dose risperidone as used in this trial maybe a preferred 
choice over aripiprazole. Otherwise, aripiprazole would 
be the preferred choice over risperidone in most situa-
tions based upon metabolic outcome advantages and 
some symptom advantages within the context of  simi-
lar results between medications on positive symptom 
response. We did not anticipate a difference between 
agents in depressive symptoms. Our SAFTEE-SI and 
post hoc BPRS analyses may be useful for hypoth-
esis generation for future depressive symptom focused 
schizophrenia studies.
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